Azithromycin in acute upper gastrointestinal bleeding: a multicentric, double-blind, randomized-controlled trial (CLEAN-AZ)
Endoscopy · 01.06.2026 · 58 (S 03 S 03) · S184-S185
DOI: 10.1055/s-0046-1822906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von A M Voiosu und 18 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Current guidelines recommend prokinetic agents for gastric cleansing prior to endoscopy for acute upper gastrointestinal (UGI) bleeding in order to enhance visibility and reduce the need for reintervention [ 1 ]. Erythromycin is recommended but not available in all healthcare systems and azythromycin has been studied as a potentially more effective alternative. Our study assessed the efficacy and safety of intravenous azithromycin as pre-endoscopic prokinetic in patients undergoing emergent UGI endoscopy for acute bleeding.
Methods
This was a prospective, multicenter, randomized, double-blind, placebo-controlled trial conducted in 12 hospitals in Romania (NCT06077916). Adult patients with acute UGI bleeding less than 12 hours after onset were randomized to either 500 mg intravenous azithromycin (AZT group) in 250 mL of saline or 250 mL saline (placebo group) administered 30-90 minutes prior to endoscopy. Our primary outcomes were: quality of visualization according to Toronto UGI Cleaning Score (TUGCS) [ 2 ] and the need to repeat endoscopy due to poor visibility. Our secondary outcomes included: adverse events, TUGCS subscores per segment, transfusion requirements, duration of the procedure, length of hospital stay, and endoscopist satisfaction regarding visibility measured on a 5-point Likert scale. We estimated a need to enroll 224 patients in order to obtain 90% chance of detecting a clinically-relevant increase in adequate visualization (defined by TUGCS≥8 ) from 60 to 80%.
Results
We randomized 224 patients but included 188 in the per-protocol analysis (93 AZT, 95 CTR). The primary outcome was not met as TUGCS≥8 was reported in 79/93 patients (84.9%) in the AZT compared with 70/95 patients (73.7%) in the placebo group (p=0.07). However, endoscopists were significantly more satisfied by the intraprocedural visibility achieved in the AZT group compared to placebo (77/93 rated good or excellent vs 62/95, p=0.008). There was no statistically significant difference between groups in: need for repeat endoscopy due to poor visualization, TUGCS subscores, duration of the procedure, length of hospital stay, or units of blood transfused. There were 3 instances of potentially AZT-related adverse events (1 diarrhea, 1 severe vomiting, 1 Clostridium difficile infection) but no allergic reactions or arrhythmia. The incidence of adverse events was low and comparable between groups, with no significant differences in rebleeding (6/93 vs 6/95, p=1), in-hospital mortality (4/93 vs. 6/95, p=0.7), or need for endoscopic hemostatic intervention (44/93 vs. 45/95; p=0.9).
Conclusions
In the per protocol analysis, i.v. azithromycin administered prior to endoscopy in patients with acute UGI bleeding was safe and well tolerated. While it did not significantly improve the Toronto UGI cleaning score or reduce the need for repeat endoscopy, azithromycin was associated with higher endoscopist satisfaction regarding visibility. Publication History Article published online: 05 June 2026 © 2026. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Voiosu, A. M., Rouhani, F., Amza, T. I., Bengus, A., Constantinescu, G., Dumitru, A., Dumitru, E., Gheonea, D. I., Moga, T., Pavel, C., Rizescu, V., Popescu, A., Sacerdoțianu, V. M., Saftoiu, A., Tocia, C., Ungureanu, B. S., Voiosu, T., Clean-Az, W. G., & Mateescu, R. B. (2026). Azithromycin in acute upper gastrointestinal bleeding: a multicentric, double-blind, randomized-controlled trial (CLEAN-AZ). Endoscopy, 58(S 03 S 03), S184-S185. https://doi.org/10.1055/s-0046-1822906
Vancouver
Voiosu AM, Rouhani F, Amza TI, Bengus A, Constantinescu G, Dumitru A, et al. Azithromycin in acute upper gastrointestinal bleeding: a multicentric, double-blind, randomized-controlled trial (CLEAN-AZ). Endoscopy. 2026;58(S 03 S 03):S184-S185. doi:10.1055/s-0046-1822906
BibTeX
@article{Voiosu2026,
author = {Voiosu, A M and Rouhani, F and Amza, T I and Bengus, A and Constantinescu, G and Dumitru, A and Dumitru, E and Gheonea, D I and Moga, T and Pavel, C and Rizescu, V and Popescu, A and Sacerdoțianu, V M and Saftoiu, A and Tocia, C and Ungureanu, B S and Voiosu, T and Clean-Az, W G and Mateescu, R B},
title = {Azithromycin in acute upper gastrointestinal bleeding: a multicentric, double-blind, randomized-controlled trial (CLEAN-AZ)},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {S 03 S 03},
pages = {S184--S185},
doi = {10.1055/s-0046-1822906}
}
EUVIMED